Background
Methods
Study design and patient recruitment
Statistical analysis
Results
Patient demographic characteristics
Variables | Subgroups | Development set (n = 96) No. of patients (%) Median (range) | Temporal validation set (n = 24) No. of patients (%) Median (range) | P value |
---|---|---|---|---|
Outcome | Non MSE | 26 (27.1) | 4 (16.7) | 0.292 |
MSE | 70 (72.9) | 20 (83.3) | ||
Gender | Male | 46 (47.9) | 15 (62.5) | 0.201 |
Female | 50 (52.1) | 9 (37.5) | ||
Age at onset | EOMG | 62 (64.6) | 16 (66.7) | 0.815 |
LOMG | 25 (26.0) | 5 (20.8) | ||
Elderly-onset MG | 9 (9.6) | 3 (12.5) | ||
MGFA classification | II | 62 (64.6) | 16 (66.7) | 0.999 |
III | 29 (30.2) | 7 (29.2) | ||
IV | 5 (5.2) | 1 (4.2) | ||
Thymoma | No | 62 (66.0) | 19 (79.2) | 0.213 |
Yes | 32 (34.0) | 5 (20.8) | 0.633 | |
Thymectomy | No | 70 (74.5) | 19 (79.2) | |
Yes | 24 (25.5) | 5 (20.8) | ||
Worsening | No | 24 (25.0) | 9 (37.5) | 0.22 |
Yes | 72 (75.0) | 15 (62.5) | ||
Autoimmune disease | No | 86 (89.6) | 20 (83.3) | 0.619 |
Yes | 10 (10.4) | 4 (16.7) | ||
Disease duration, months | 7 (3.0–30.5) | 4 (2.0–14.5) | 0.305 | |
Anti-AChR Abs titer, nmol/L | 6 (2.6–10.3) | 8 (2.6–12.4) | 0.316 | |
Pyridostigmine dosage, mg/day | 180 (90.0–180.0) | 180 (180.0–180.0) | 0.557 | |
MMT score | 14 (7.0–19.0) | 14 (7.3–19.8) | 0.743 | |
MG-ADL score | 5 (4.0–8.0) | 5 (4.0–7.0) | 0.377 | |
Bulbar score | 2 (1.0–3.0) | 1 (0–2.8) | 0.145 | |
Respiratory score | 0 (0–1.0) | 0 (0–0) | 0.035* | |
Limb score | 1 (0–2.0) | 0 (0–1.0) | 0.103 | |
Ocular score | 3 (1.0–4.0) | 3 (2.0–4.0) | 0.182 | |
QMG score | 11 (9.0–14.0) | 12 (7.0–16.0) | 0.638 | |
Extraocular muscle score | 3 (1.0–4.0) | 4 (2.0–5.0) | 0.038 | |
Bulbar muscle score | 0 (0–1.0) | 1 (0–2.0) | 0.110 | |
Respiratory muscle score | 0 (0–1.0) | 0 (0–0) | 0.002* | |
Gross motor score | 6 (4.0–8.0) | 6 (2.5–8.0) | 0.220 | |
Axial motor score | 1 (1.0–2.0) | 1 (1.0–2.0) | 0.869 |
Variables | Subgroups | Development set (n = 96) No. of patients (%) Median (range) | External validation set (n = 45) No. of patients (%) Median (range) | P value |
---|---|---|---|---|
Outcome | Non MSE | 26 (27.1) | 12 (26.7) | 0.959 |
MSE | 70 (72.9) | 33 (73.3) | ||
Gender | Male | 46 (47.9) | 22 (48.9) | 0.914 |
Female | 50 (52.1) | 23 (51.1) | ||
Age at onset | EOMG | 62 (64.6) | 23 (51.1) | 0.096 |
LOMG | 25 (26.0) | 12 (26.7) | ||
Elderly-onset MG | 9 (9.6) | 10 (22.2) | ||
MGFA classification | II | 62 (64.6) | 21 (46.7) | 0.128 |
III | 29 (30.2) | 20 (44.4) | ||
IV | 5 (5.2) | 4 (8.9) | ||
Thymoma | No | 62 (66.0) | 32 (71.1) | 0.543 |
Yes | 32 (34.0) | 13 (28.9) | ||
Thymectomy | No | 70 (74.5) | 41 (91.1) | 0.022* |
Yes | 24 (25.5) | 4 (8.9) | ||
Worsening | No | 24 (25.0) | 7 (15.6) | 0.207 |
Yes | 72 (75.0) | 38 (84.4) | ||
Autoimmune disease | No | 86 (89.6) | 37 (82.2) | 0.222 |
Yes | 10 (10.4) | 8 (17.8) | ||
Disease duration, months | 7 (3.0–30.5) | 2 (1.0–6.0) | 0.001* | |
Anti-AChR Abs titer, nmol/L | 6 (2.6–10.3) | 8 (4.5–20.1) | 0.018* | |
Pyridostigmine dosage, mg/day | 180 (90.0–180.0) | 180 (0–210.0) | 0.528 | |
MMT score | 14 (7.0–19.0) | 50 (41.5–50)# | 0.001* | |
MG-ADL score | 5 (4.0–8.0) | 6 (4.0–9.5) | 0.151 | |
Bulbar score | 2 (1.0–3.0) | 2 (1.0–4.0) | 0.026* | |
Respiratory score | 0 (0–1.0) | 0 (0–1.0) | 0.540 | |
Limb score | 1 (0–2.0) | 0 (0–2.0) | 0.651 | |
Ocular score | 3 (1.0–4.0) | 3 (2.0–4.0) | 0.458 | |
QMG score | 11 (9.0–14.0) | 10 (7.0–16.5) | 0.485 | |
Extraocular muscle score | 3 (1.0–4.0) | 3 (2.5–4.5) | 0.068 | |
Bulbar muscle score | 0 (0–1.0) | 1 (0–3.0) | 0.001* | |
Respiratory muscle score | 0 (0–1.0) | 0 (0–1.0) | 0.357 | |
Gross motor score | 6 (4.0–8.0) | 5 (2.0–8.5) | 0.042* | |
Axial motor score | 1 (1.0–2.0) | 1 (0–2.0) | 0.097 |
Short-term clinical outcome assessment
Nomogram development and validation
Variables | Subgroups | Univariate analysis | Multivariate analysis** | ||||
---|---|---|---|---|---|---|---|
OR | 95% CI | P value | OR | 95% CI | P value | ||
Gender | Male | 1 | |||||
Female | 0.5 | 0.19–1.25 | 0.146 | ||||
Age at onset | EOMG | 1 | |||||
LOMG | 1.2 | 0.42–3.73 | 0.744 | ||||
Elderly-onset MG | 0.76 | 0.18–3.90 | 0.713 | ||||
MGFA classification | II | 1 | |||||
III | 1.19 | 0.44–3.45 | 0.741 | ||||
IV | 0.57 | 0.09–4.58 | 0.553 | ||||
Thymoma | Yes | 1 | |||||
No | 0.71 | 0.25–1.86 | 0.494 | ||||
Thymectomy | No | 1 | |||||
Yes | 2.2 | 0.73–8.23 | 0.192 | ||||
Worsening | Yes | ||||||
No | 2.36 | 0.78–8.80 | 0.155 | ||||
Autoimmune disease | No | 1 | |||||
Yes | 0.85 | 0.22–4.21 | 0.827 | ||||
MMT score | > 26 | 1 | |||||
≤ 26 | 2.36 | 0.54–9.72 | 0.229 | ||||
Anti-AChR Abs titer, nmol/L | > 9 | 1 | |||||
≤ 9 | 0.49 | 0.15–1.37 | 0.197 | ||||
Duration, months | > 12 | 1 | 1 | ||||
≤ 12 | 4.41 | 1.73–11.90 | 0.002** | 3.45 | 1.23–10.24 | 0.021 | |
Pyridostigmine dosage, mg/day | ≤ 240 | ||||||
> 240 | 0.46 | 0.10–2.50 | 0.339 | ||||
MG-ADL score | > 3 | 1 | |||||
≤ 3 | 2.74 | 0.69–18.36 | 0.207 | ||||
Bulbar score | ≤ 1 | 1 | |||||
> 1 | 2.01 | 0.81–5.19 | 0.136 | ||||
Respiratory function | Normal | 1 | |||||
Abnormal | 1.53 | 0.56–4.65 | 0.426 | ||||
Limb score | ≤ 1 | 1 | |||||
> 1 | 1.51 | 0.57–4.31 | 0.418 | ||||
Ocular score | > 2 | 1 | |||||
≤ 2 | 2.87 | 1.11–8.15 | 0.036** | 6.00 | 1.82–24.58 | 0.006 | |
QMG score | ≤ 13 | 1 | 1 | ||||
> 13 | 2.36 | 0.78–8.80 | 0.155 | 11.95 | 2.31–95.82 | 0.008 | |
Extraocular muscle score | ≥ 1 | 1 | |||||
0 | 2.52 | 0.84–9.39 | 0.124 | ||||
Bulbar muscle score | ≥ 1 | 1 | |||||
0 | 0.51 | 0.17–1.37 | 0.198 | ||||
Respiratory muscle score | ≥ 80 | 1 | |||||
65–79 | 0.98 | 0.36–2.79 | |||||
50–64 | 0.75 | 0.28–9.48 | |||||
< 50 | 0.81 | 0.07–16.83 | |||||
Gross motor score | > 9 | 1 | 1 | ||||
≤ 9 | 2.67 | 0.90–7.81 | 0.072* | 10.82 | 2.22–69.13 | 0.006 | |
Axial motor score | > 2 | 1 | |||||
≤ 2 | 1.70 | 0.33–7.48 | 0.493 |